research use only

Amfebutamone (Bupropion) HCl AChR inhibitor

Name: Amfebutamone (Bupropion) HCl
Brand: Selleck Chemicals
SKU: S2452
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S2452

Amfebutamone (Bupropion) HCl(Wellbutrin) is a selective norepinephrine-dopamine reuptake inhibitor with IC50 of 6.5 and 3.4 μM for the reuptake of dopamine and norepinephrine, respectively.

Amfebutamone (Bupropion) HCl AChR inhibitor Chemical Structure

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Adrenergic Receptor 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other AChR Inhibitors	PNU-120596 Benzethonium Chloride Arecoline HBr Otilonium Bromide Palmatine Lycorine Nitenpyram PNU 282987 HCl Chelidonine Hyoscyamine

Solubility

In vitro
Batch:

DMSO : 8 mg/mL (28.96 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.4mg/ml (1.45mM)	Taking the 1 mL working solution as an example, add 50 μL of 8 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	276.2	Formula	C₁₃H₁₈ClNO.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	31677-93-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Wellbutrin			SMILES	CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Dopamine receptor AChR
References	[1] https://pubmed.ncbi.nlm.nih.gov/9862757/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-08)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07398404	NOT_YET_RECRUITING	Obesity; Smoking Cessation; Bariatric Surgery Patients	Medical University of South Carolina	2026-09-01	PHASE1; PHASE2
NCT07714200	NOT_YET_RECRUITING	Tobacco Use Disorder	VA Office of Research and Development	2027-03-01
NCT02129751	NOT_YET_RECRUITING	Major Depressive Disorder	Bausch Health Americas, Inc.	2026-06	PHASE4
NCT06098079	ACTIVE_NOT_RECRUITING	Obesity	Currax Pharmaceuticals	2024-01-03	PHASE4
NCT04604509	RECRUITING	Cigarette Smoking-Related Carcinoma	M.D. Anderson Cancer Center	2020-08-04	PHASE4
NCT07596212	NOT_YET_RECRUITING	Early-stage Breast Cancer; Hypoactive Sexual Desire Disorder; Hormone Receptor Positive Breast Carcinoma; Breast Cancer	University of Illinois at Chicago	2026-09	PHASE1; PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):